biote Corp.
NASDAQ:BTMDMedical - Care Facilities
+$0.01 today
- Market cap
- $54.25M
- Beta
- 1.66
- P/E (TTM)
- 4.5
- EPS (TTM)
- $0.51
Volume 0.11M
Average 0.25M
BTMD Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
biote Corp.NASDAQ: BTMD
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $25.67M rose 2.3% year over year, ahead of the -11.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at -17.8% a year.
Context
- Selling, general & admin amounted to 49.4% of revenue in FY2025, down 5.1 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $107.94M (+13.7%) for the fiscal year ending Dec 2026, a step up from the -11.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $25.67M+8.7% QoQ
- Last fiscal yearDec 2025
- $94.97M-11.6% YoY
- LTMMar 2026
- $96.82M-11.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 94.97M USD
- Year-over-year change
- -11.6%
- 4-year CAGR
- +15.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 94.97M | -11.6% |
| FY2024 | 2024-12-31 | 107.45M | +8.7% |
| FY2023 | 2023-12-31 | 98.83M | -42.2% |
| FY2022 | 2022-12-31 | 171.1M | +217.1% |
| FY2021 | 2021-12-31 | 53.96M | — |
Selling, General & Admin vs competitors
How BTMD compares with its peers on the latest reported figures
- BTMD's LTM Mar 2026 selling, general & admin of $96.82M is the 4th highest of the 11 companies compared; the peer median is $47.12M.
- Its year-over-year change of -11.5% is the 9th highest of 11, against a peer median of +73.5%.
- Selling, general & admin amounts to 51.5% of revenue for BTMD, versus a peer median of 436.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.08B | +51937.5% | +914.5% | 391112.6% | |
| LTM Mar 2026 | $16.46B | +48531.9% | -28.7% | — | |
| LTM Mar 2026 | $269.6M | +128.9% | +60.2% | 796.2% | |
| LTM Mar 2026 | $96.82M | -11.5% | -17.8% | 51.5% | |
| LTM Mar 2026 | $53.95M | +26.2% | -1.4% | 46.4% | |
| LTM Mar 2026 | $51.12M | +107.0% | +36.0% | — | |
| LTM Mar 2026 | $43.12M | +319.1% | -19.4% | 76.1% | |
| LTM Mar 2026 | $35.34M | -27.5% | -17.7% | 3080.9% | |
| LTM Mar 2026 | $19.24M | -21.8% | -16.6% | 35.1% | |
| LTM Mar 2026 | $18.46M | -7.7% | +13.7% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $12.2M | +39.9% | +47.3% | — |
| Peer median (excluding BTMD) | $47.12M | +73.5% | +6.2% | 436.2% | |
Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.4M | 164.96M | 185.36M | 197.19M | 192.22M |
| Cost of Revenue | 48.82M | 54.58M | 57.88M | 58.13M | 58.13M |
| Gross Profit | 90.58M | 110.38M | 127.48M | 139.06M | 134.09M |
| Gross Margin | 65.0% | 66.9% | 68.8% | 70.5% | 69.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 53.96M | 171.1M | 98.83M | 107.45M | 94.97M |
| Operating Expenses | 56.02M | 171.1M | 98.83M | 107.45M | 94.97M |
| Depreciation & Amortization | 1.4M | 2.2M | 794K | 3.57M | 3.67M |
| EBITDA | 35.98M | 7.96M | 39.54M | 15.59M | 53.12M |
| EBITDA Margin | 25.8% | 4.8% | 21.3% | 7.9% | 27.6% |
| Operating Income | 34.56M | (60.72M) | 28.66M | 31.61M | 39.12M |
| Operating Margin | 24.8% | -36.8% | 15.5% | 16.0% | 20.4% |
| Interest Income | 0 | 0 | 0 | 0 | 900K |
| Interest Expense | 1.67M | 4.05M | 6.36M | 11M | 11.86M |
| Other Income / Expenses | (1.66M) | 62.43M | (28.78M) | (30.6M) | (1.54M) |
| Income Before Tax | 32.91M | 1.71M | (123K) | 1.02M | 37.58M |
| Pre-Tax Margin | 23.6% | 1.0% | -0.1% | 0.5% | 19.6% |
| Income Tax Expense | 286K | 388K | 2.68M | 970K | 5.99M |
| Net Income | 32.62M | (969K) | 3.32M | 3.16M | 27.05M |
| Net Margin | 23.4% | -0.6% | 1.8% | 1.6% | 14.1% |
| EPS (Basic) | (0.87) | 0.16 | 0.13 | 0.09 | 0.86 |
| EPS (Diluted) | (0.87) | 0.16 | 0.13 | 0.09 | 0.74 |
| Weighted Avg Shares | 7.57M | 8.06M | 25.71M | 34.27M | 31.28M |
| Weighted Avg Shares (Diluted) | 7.57M | 8.06M | 25.71M | 34.27M | 36.67M |
biote Corp.
NASDAQ:BTMD
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.